clinical trial · NCT07247110
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC·phase1·recruiting·n = 250
Malignant NeoplasmMK-4716PembrolizumabCetuximab
brief summary
Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
started
Dec 16, 2025
primary completion
Dec 1, 2030
completion
Dec 1, 2030
last updated
May 14, 2026
official title
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol